125 related articles for article (PubMed ID: 16682217)
1. Manufacturing and supply of monovalent oral polio vaccines.
Graf H
Biologicals; 2006 Jun; 34(2):141-4. PubMed ID: 16682217
[TBL] [Abstract][Full Text] [Related]
2. Licensing of monovalent OPV1 vaccine.
Farag MM
Biologicals; 2006 Jun; 34(2):145-9. PubMed ID: 16672188
[TBL] [Abstract][Full Text] [Related]
3. Monovalent polio immunisation--a strategy for India.
Chatterjee A; Chawla A
J Indian Med Assoc; 2005 Dec; 103(12):682-5. PubMed ID: 16821665
[TBL] [Abstract][Full Text] [Related]
4. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
[TBL] [Abstract][Full Text] [Related]
6. Risk management in a polio-free world.
Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
[TBL] [Abstract][Full Text] [Related]
7. Role of genetic factors in polio eradication: new challenge for policy makers.
Paul Y
Vaccine; 2007 Dec; 25(50):8365-71. PubMed ID: 17996995
[TBL] [Abstract][Full Text] [Related]
8. Experience with vero cells at Pasteur Mérieux Connaught.
Montagnon BJ; Vincent-Falquet JC; Saluzzo JF
Dev Biol Stand; 1999; 98():137-40; discussion 167. PubMed ID: 10494966
[TBL] [Abstract][Full Text] [Related]
9. Progress toward interruption of wild poliovirus transmission--worldwide, January 2007-April 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 May; 57(18):489-94. PubMed ID: 18463607
[TBL] [Abstract][Full Text] [Related]
10. New assays for the quality control of live oral poliovirus vaccine.
Furesz J; Levenbook I
Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
[TBL] [Abstract][Full Text] [Related]
11. Use of oral polio vaccine for polio eradication.
Bhatnagar P; Bahl S; Biswal P
J Indian Med Assoc; 2005 Dec; 103(12):680-1. PubMed ID: 16821664
[TBL] [Abstract][Full Text] [Related]
12. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
13. Progress toward interruption of wild poliovirus transmission--worldwide, January 2006-May 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Jul; 56(27):682-5. PubMed ID: 17625496
[TBL] [Abstract][Full Text] [Related]
14. Technology transfer of Sabin-IPV to new developing country markets.
Kreeftenberg H; van der Velden T; Kersten G; van der Heuvel N; de Bruijn M
Biologicals; 2006 Jun; 34(2):155-8. PubMed ID: 16650773
[TBL] [Abstract][Full Text] [Related]
15. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
Furesz J
Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
[TBL] [Abstract][Full Text] [Related]
16. Progress toward poliomyelitis eradication--Nigeria, 2005-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(12):278-81. PubMed ID: 17392680
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
18. Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents.
Kops SP
Anticancer Res; 2000; 20(6C):4745-9. PubMed ID: 11205211
[TBL] [Abstract][Full Text] [Related]
19. A vision of a world without polio: the OPV cessation strategy.
Heymann DL; Sutter RW; Aylward RB
Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
[TBL] [Abstract][Full Text] [Related]
20. The global eradication of poliomyelitis: progress and problems.
Rey M; Girard MP
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):317-25. PubMed ID: 17923156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
